$-0.10 EPS Expected for Midatech Pharma Plc (MTP)

March 15, 2018 - By Michael Collier

 $ 0.10 EPS Expected for Midatech Pharma Plc (MTP)

Analysts expect Midatech Pharma Plc (NASDAQ:MTP) to report $-0.10 EPS on April, 2. The stock increased 1.71% or $0.0156 during the last trading session, reaching $0.9257. About 15,827 shares traded. Midatech Pharma Plc (NASDAQ:MTP) has 0.00% since March 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Midatech Pharma PLC, a specialty pharmaceutical company, focuses on the development and commercialization of oncology and other therapeutic products in the United Kingdom, Turkey, other European countries, and the United States. The company has market cap of $25.04 million. It offers Oravig, an orally dissolving buccal tablet for oral thrush and oropharyngeal candidiasis in adults; Gelclair, an oral rinse gel for the management and relief of pain arising from oral lesions of various etiologies; Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; and Soltamox, an oral liquid solution of tamoxifen citrate for the prevention of breast cancer. It currently has negative earnings. The firm also engages in the marketing of Ferralet 90, a prescription iron supplement for the treatment of anemias that are responsive to oral iron therapy; and Aquoral, an artificial saliva spray to provide relief from chemotherapy/radiation therapy.

More news for Midatech Pharma Plc (NASDAQ:MTP) were recently published by: Quotes.Wsj.com, which released: “Midatech Pharma PLC ADR MTP (US: Nasdaq)” on February 12, 2011. Marketwatch.com‘s article titled: “Midatech Pharma PLC ADR” and published on June 07, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: